Company: ANIX
Filing Date: 2025-09-10
Form Type: 10-Q
Source: 0001493152-25-013000
Chunk: 9

Company: Anixa Biosciences Inc
Filing Date: 2025-09-10
Form: 10-Q
Item: Part I, Item 1
Chunk 9
---
 from sale of common stock in an at-the-market offering, net of offering expenses of $123 and $139, respectively 
     1,924  
     2,984 
  
    Proceeds
    from sale of common stock pursuant to an employee stock purchase plan 
     4  
     7 
  
    Proceeds
    from exercise of stock options 
     2  
     318 
  
    Net
    cash provided by financing activities 
     1,930  
     3,309 

    Net
    increase in cash and cash equivalents 
     224  
     310 
  
    Cash
    and cash equivalents at beginning of period 
     1,271  
     915 
  
    Cash
    and cash equivalents at end of period 
    $1,495  
    $1,225 

    Supplemental
    disclosure of non-cash investing activity: 

    Operating
    lease right-of-use asset from lease extension 
    $-  
    $(100)

    Supplemental
    disclosure of non-cash financing activity: 

    Operating
    lease liability from lease extension 
    $-  
    $100 

The
accompanying notes are an integral part of these condensed consolidated financial statements.

5

ANIXA
BIOSCIENCES, INC. AND SUBSIDIARIES

NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

1.
BUSINESS AND FUNDING

Description
of Business

As
used herein, “we,” “us,” “our,” the “Company” or “Anixa” means Anixa Biosciences,
Inc. and its consolidated subsidiaries.

Anixa
Biosciences, Inc. is a biotechnology company developing therapies and vaccines that are focused on critical unmet needs in oncology.
Our therapeutics program consists of the development of a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen
receptor-T cell (“CAR-T”) technology, initially focused on treating ovarian cancer, which is being developed at our subsidiary,
Certainty Therapeutics, Inc. (“Certainty”). Our vaccine programs include (i) the development of a vaccine against breast
cancer, initially focused on triple negative breast cancer (“TNBC”), the most lethal form of breast cancer, (ii) the development
of a vaccine against ovarian cancer, and